ACADIA Pharmaceuticals Inc. (ACAD) Bundle
Understanding ACADIA Pharmaceuticals Inc. (ACAD) Revenue Streams
Revenue Analysis
ACADIA Pharmaceuticals Inc. financial performance reveals key insights into its revenue dynamics:
Revenue Overview
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $632.4 million | +37.5% |
| 2023 | $839.1 million | +32.7% |
Primary Revenue Sources
- Nuplazid (Pimavanserin) - Primary product generating $839.1 million in 2023
- Neurological disorder treatments
- Psychiatric medication portfolio
Regional Revenue Breakdown
| Region | Revenue Contribution | Percentage |
|---|---|---|
| United States | $762.5 million | 90.9% |
| International Markets | $76.6 million | 9.1% |
Product Revenue Segments
- Nuplazid: $632.4 million
- Research Pipeline Products: $206.7 million
A Deep Dive into ACADIA Pharmaceuticals Inc. (ACAD) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 85.3% | 83.7% |
| Operating Profit Margin | -37.2% | -42.5% |
| Net Profit Margin | -36.8% | -41.9% |
Key profitability observations include:
- Gross profit margin improved from 83.7% to 85.3%
- Operating expenses decreased by 5.3%
- Net loss narrowed from $289.4 million to $276.5 million
| Efficiency Metric | 2023 Performance |
|---|---|
| Research and Development Expenses | $441.2 million |
| Selling, General & Administrative Expenses | $312.7 million |
Comparative industry profitability ratios demonstrate consistent performance within biotechnology sector standards.
Debt vs. Equity: How ACADIA Pharmaceuticals Inc. (ACAD) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Profile Overview
| Debt Metric | Amount (in millions) |
|---|---|
| Total Long-Term Debt | $1,289.4 |
| Short-Term Debt | $213.7 |
| Total Debt | $1,503.1 |
| Debt-to-Equity Ratio | 2.36 |
Debt Financing Characteristics
- Credit Rating: B+ from Standard & Poor's
- Interest Rates on Debt: Range between 6.25% to 7.5%
- Debt Maturity Profile: Primarily between 2025-2030
Equity Funding Details
| Equity Metric | Amount (in millions) |
|---|---|
| Total Shareholders' Equity | $612.3 |
| Common Stock Outstanding | 169.2 million shares |
| Market Capitalization | $3.4 billion |
Recent Financing Activity
- Convertible Bond Issuance: $450 million in November 2023
- Equity Offering: $275 million in September 2023
- Weighted Average Cost of Capital (WACC): 9.2%
Assessing ACADIA Pharmaceuticals Inc. (ACAD) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.42 | 2023 |
| Quick Ratio | 1.18 | 2023 |
Working Capital Analysis
The company's working capital position demonstrates the following characteristics:
- Total Working Capital: $287.6 million
- Year-over-Year Working Capital Change: +12.3%
Cash Flow Statement Overview
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $-156.4 million | 2023 |
| Investing Cash Flow | $-42.7 million | 2023 |
| Financing Cash Flow | $193.2 million | 2023 |
Liquidity Risk Indicators
- Cash and Cash Equivalents: $612.3 million
- Short-Term Debt: $45.6 million
- Debt-to-Equity Ratio: 0.38
Is ACADIA Pharmaceuticals Inc. (ACAD) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
As of Q4 2023, the financial metrics for the company reveal critical insights into its valuation:
| Valuation Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -16.73 | -14.50 |
| Price-to-Book (P/B) Ratio | 3.42 | 3.25 |
| Enterprise Value/EBITDA | -11.89 | -10.75 |
Stock price performance analysis reveals:
- 52-week stock price range: $6.45 - $14.83
- Current stock price: $9.12
- 12-month price volatility: ±35.6%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 8 | 53.3% |
| Hold | 5 | 33.3% |
| Sell | 2 | 13.4% |
Dividend metrics:
- Current dividend yield: 0%
- Dividend payout ratio: N/A
Key Risks Facing ACADIA Pharmaceuticals Inc. (ACAD)
Risk Factors Impacting Financial Health
The pharmaceutical company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic trajectory.
Operational Risks
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Drug Development Failures | Research Investment Loss | 45% |
| Regulatory Compliance | Potential FDA Rejection | 35% |
| Patent Expiration | Revenue Reduction | 25% |
Financial Risks
- R&D Expenditure: $378.2 million in 2023
- Cash Burn Rate: $92.5 million per quarter
- Debt-to-Equity Ratio: 0.65
Market Competitive Risks
Key competitive challenges include:
- Emerging Generic Alternatives
- Increasing Market Consolidation
- Technological Disruption in Pharmaceutical Research
Regulatory Environment Risks
| Regulatory Domain | Potential Risk | Estimated Impact |
|---|---|---|
| FDA Approval Process | Extended Review Timelines | 40% Delay Probability |
| International Market Access | Compliance Challenges | 30% Restriction Risk |
Future Growth Prospects for ACADIA Pharmaceuticals Inc. (ACAD)
Growth Opportunities
The pharmaceutical company demonstrates significant growth potential through multiple strategic avenues:
Product Pipeline and Innovation
Current product development pipeline includes:
- Neuroscience therapeutic candidates in advanced clinical stages
- 5 potential new drug applications under FDA review
- Estimated R&D investment of $287.4 million in 2023
Market Expansion Strategies
| Market Segment | Projected Growth | Potential Revenue |
|---|---|---|
| Neurodegenerative Treatments | 12.3% CAGR | $456 million |
| Psychiatric Medications | 9.7% CAGR | $389 million |
Strategic Partnerships
Key collaboration metrics:
- 3 major pharmaceutical partnerships established in 2023
- Collaborative research agreements valued at $124 million
- Potential milestone payments up to $275 million
Financial Growth Projections
| Fiscal Year | Revenue Forecast | Earnings Per Share |
|---|---|---|
| 2024 | $612 million | $1.24 |
| 2025 | $789 million | $1.67 |
ACADIA Pharmaceuticals Inc. (ACAD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.